Envisioning Our Future for Children: "Al and Microphysiological Systems Transforming Biomedicine"
Why It Matters
The move to AI and human‑based microphysiological models will slash development timelines and costs while ensuring compliance with upcoming global bans on animal testing, reshaping the entire biotech landscape.
Key Takeaways
- •AI and microphysiological systems are replacing animal testing rapidly.
- •Regulatory agencies worldwide set 2035 deadlines to end animal tests.
- •Exponential tech growth outpaces chemical registration, demanding new methods.
- •FDA collaboration accelerates adoption of human‑based preclinical models.
- •AI accuracy now rivals expert scientists, reducing toxicology uncertainty.
Summary
Professor Thomas Hartung opened the session by framing a historic transition: after 35 years of advocating alternatives, AI and microphysiological systems are now poised to supplant traditional animal testing in biomedical research. He highlighted how organ‑on‑a‑chip technologies and advanced computational models are reshaping toxicology, drug safety, and broader pre‑clinical science.
Hartung cited a wave of regulatory commitments—FDA’s 2024 roadmap, EPA’s 2035 animal‑testing ban, NIH’s human‑based research priority, and parallel UK and EU strategies—demonstrating unprecedented policy tailwinds. He underscored exponential technological progress: mass‑spectrometry sensitivity improves every 3‑4 years, genome‑sequencing costs drop 1.4‑year cycles, and AI model capacity doubles roughly every three months, outpacing the registration of 350,000 chemicals, 90% of which lack safety data.
Using vivid analogies, Hartung compared the current shift to the horse‑car revolution, noting that animal studies predict human outcomes with only 45‑80% accuracy. He pointed out AI’s rapid maturation—from early gimmicks to models with sub‑1% hallucination rates—now delivering expert‑level insights in minutes, dramatically reducing uncertainty in toxicology assessments.
The implications are clear: companies that adopt AI‑driven microphysiological platforms can accelerate drug development, cut billions in R&D costs, and stay ahead of looming regulatory bans. The convergence of policy pressure and exponential tech growth makes the transition not just desirable but inevitable for the pharmaceutical and chemical industries.
Comments
Want to join the conversation?
Loading comments...